Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ANNX NYSE:GLAS NASDAQ:PHAT NASDAQ:VYGR On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.80-2.4%$5.36$2.03▼$7.18$973.22M1.164.68 million shs2.74 million shsGLASGlass House Brands$11.67+0.5%$0.00$4.55▼$13.93$936.94MN/A245,842 shs213,418 shsPHATPhathom Pharmaceuticals$12.61+3.7%$11.09$7.61▼$18.31$969.83M0.49960,682 shs2.32 million shsVYGRVoyager Therapeutics$3.44-6.5%$3.71$2.88▼$5.55$222.35M1.27659,393 shs715,897 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.36%+6.23%+22.88%-0.85%+109.39%GLASGlass House Brands+3.35%-5.64%+1,167,199,900.00%+1,167,199,900.00%+1,167,199,900.00%PHATPhathom Pharmaceuticals+3.70%+12.59%+28.41%-0.16%+34.58%VYGRVoyager Therapeutics-6.52%-8.99%+3.61%-8.02%-0.86%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeANNXAnnexon$5.80-2.4%$5.36$2.03▼$7.18$973.22M1.164.68 million shs2.74 million shsGLASGlass House Brands$11.67+0.5%$0.00$4.55▼$13.93$936.94MN/A245,842 shs213,418 shsPHATPhathom Pharmaceuticals$12.61+3.7%$11.09$7.61▼$18.31$969.83M0.49960,682 shs2.32 million shsVYGRVoyager Therapeutics$3.44-6.5%$3.71$2.88▼$5.55$222.35M1.27659,393 shs715,897 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceANNXAnnexon-2.36%+6.23%+22.88%-0.85%+109.39%GLASGlass House Brands+3.35%-5.64%+1,167,199,900.00%+1,167,199,900.00%+1,167,199,900.00%PHATPhathom Pharmaceuticals+3.70%+12.59%+28.41%-0.16%+34.58%VYGRVoyager Therapeutics-6.52%-8.99%+3.61%-8.02%-0.86%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceANNXAnnexon 2.43Hold$16.00175.86% UpsideGLASGlass House Brands 2.50Moderate BuyN/AN/APHATPhathom Pharmaceuticals 2.86Moderate Buy$24.5094.29% UpsideVYGRVoyager Therapeutics 2.75Moderate Buy$16.50379.65% UpsideCurrent Analyst Ratings BreakdownLatest VYGR, GLAS, ANNX, and PHAT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/1/2026GLASGlass House Brands Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageSell (D+)6/30/2026GLASGlass House Brands Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/17/2026PHATPhathom Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$26.005/26/2026VYGRVoyager Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy5/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.005/12/2026ANNXAnnexon The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageNeutral$7.004/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026ANNXAnnexon Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/15/2026VYGRVoyager Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 7/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookANNXAnnexonN/AN/AN/AN/A$1.42 per shareN/AGLASGlass House Brands$176.02M5.32N/AN/AN/A∞PHATPhathom Pharmaceuticals$175.11M5.74N/AN/A($6.14) per share-2.05VYGRVoyager Therapeutics$40.37M5.15N/AN/A$3.53 per share0.97Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateANNXAnnexon-$206.69M-$1.22N/AN/AN/AN/A-101.19%-75.99%8/13/2026 (Estimated)GLASGlass House BrandsN/AN/AN/AN/AN/AN/AN/AN/AN/APHATPhathom Pharmaceuticals-$221.25M-$2.12N/A8.08N/A-76.77%N/A-44.29%8/6/2026 (Estimated)VYGRVoyager Therapeutics-$119.72M-$1.97N/AN/AN/A-319.61%-55.97%-43.12%8/5/2026 (Estimated)Latest VYGR, GLAS, ANNX, and PHAT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026PHATPhathom Pharmaceuticals-$0.2071N/AN/AN/A$73.98 millionN/A8/5/2026Q2 2026VYGRVoyager Therapeutics-$0.55N/AN/AN/A$4.56 millionN/A5/7/2026Q1 2026ANNXAnnexon-$0.30-$0.23+$0.07-$0.23$5.50 millionN/A5/7/2026Q1 2026VYGRVoyager Therapeutics-$0.54-$0.47+$0.07-$0.47$8.79 million$1.19 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthANNXAnnexonN/AN/AN/AN/AN/AGLASGlass House BrandsN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/AVYGRVoyager TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioANNXAnnexonN/A6.356.35GLASGlass House BrandsN/AN/AN/APHATPhathom PharmaceuticalsN/A2.212.16VYGRVoyager TherapeuticsN/A8.428.42Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipANNXAnnexonN/AGLASGlass House BrandsN/APHATPhathom Pharmaceuticals99.01%VYGRVoyager Therapeutics48.03%Insider OwnershipCompanyInsider OwnershipANNXAnnexon10.31%GLASGlass House BrandsN/APHATPhathom Pharmaceuticals9.33%VYGRVoyager Therapeutics12.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableANNXAnnexon60163.84 million146.95 millionOptionableGLASGlass House BrandsN/A80.27 millionN/AN/APHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableVYGRVoyager Therapeutics10060.42 million52.75 millionOptionableVYGR, GLAS, ANNX, and PHAT HeadlinesRecent News About These CompaniesCramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime’ to Make MoneyJuly 2, 2026 | aol.comACramer to a 23-Year-Old: Buy It, but It Might Take a ‘Lifetime' to Make MoneyJuly 2, 2026 | 247wallst.comVoyager Therapeutics (VYGR) is Amongst the Best Stocks Under $10, With More Than 50% UpsideJune 30, 2026 | finance.yahoo.comVoyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026June 29, 2026 | markets.businessinsider.comVoyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026June 29, 2026 | globenewswire.comVoyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid ConferenceJune 11, 2026 | globenewswire.comVoyager Therapeutics Highlights 2026 CNS Pipeline and StrategyJune 10, 2026 | theglobeandmail.comVoyager Therapeutics Expands Authorized Shares After Stockholder VoteJune 10, 2026 | tipranks.comHere's Why We're A Bit Worried About Voyager Therapeutics' (NASDAQ:VYGR) Cash Burn SituationJune 9, 2026 | finance.yahoo.comVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s DiseaseJune 1, 2026 | markets.businessinsider.comVoyager Therapeutics IND Cleared for Alzheimer’s Gene TherapyJune 1, 2026 | tipranks.comVoyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's DiseaseJune 1, 2026 | globenewswire.comWhat Voyager Therapeutics Inc (VYGR) Has Gained on Its Therapy ProgramsMay 20, 2026 | finance.yahoo.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026May 13, 2026 | markets.businessinsider.comVoyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer's Disease Expected H2 2026May 13, 2026 | globenewswire.comVoyager Therapeutics (VYGR) Reports Q1 Loss, Misses Revenue EstimatesMay 7, 2026 | zacks.comVoyager Reports First Quarter 2026 Financial and Operating ResultsMay 7, 2026 | globenewswire.comH.C. Wainwright Reaffirms Their Buy Rating on Voyager Therapeutics (VYGR)May 1, 2026 | theglobeandmail.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s DiseaseApril 28, 2026 | markets.businessinsider.comVoyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer's DiseaseApril 27, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeVYGR, GLAS, ANNX, and PHAT Company DescriptionsAnnexon NASDAQ:ANNX$5.80 -0.14 (-2.36%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$5.92 +0.12 (+2.05%) As of 07/10/2026 06:06 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.Glass House Brands NYSE:GLAS$11.67 +0.06 (+0.53%) Closing price 07/10/2026 03:59 PM EasternExtended Trading$11.54 -0.13 (-1.11%) As of 07/10/2026 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals NASDAQ:PHAT$12.61 +0.45 (+3.70%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$12.58 -0.03 (-0.24%) As of 07/10/2026 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.Voyager Therapeutics NASDAQ:VYGR$3.44 -0.24 (-6.52%) Closing price 07/10/2026 04:00 PM EasternExtended Trading$3.52 +0.09 (+2.47%) As of 07/10/2026 07:35 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rocket Lab’s Stock Drop Comes With a Bullish Twist Micron's $250 Billion Bet Could Reshape the AI Memory Race AeroVironment Flies Under Wall Street’s Radar Toward a $4 Billion Target IQM's Nasdaq Debut Could Change the Quantum Race for D-Wave PriceSmart Stock Eyes $220 as Chile Expansion Fuels Growth PepsiCo’s Dividend Could Turn Patience Into Real Profit Lockheed Martin Secures the Ultimate Defense Moat Why Levi's Digital Strategy Is Paying Off in a Big Way Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
